Contact details

David Dowding

T: +44 20 7809 2162 M: +44 77 1242 9038 Email David | Vcard Office: London

David Dowding Senior associate

Contact details

David Dowding

David Dowding
Senior associate

T: +44 20 7809 2162 M: +44 77 1242 9038 Email David | Vcard Office: London

Specialising in corporate acquisitions and disposals and corporate finance, David has broad experience advising both corporate clients and investment banks on equity capital markets transactions (Official List and AIM). David has particular experience in the healthcare and energy and resources sectors. Clients value his responsiveness and his measured approach to complex issues.
  • Profile
  • Services
  • Sectors

David advises on a broad range of corporate finance and M&A (public and private) matters. As well as regularly advising private companies, he is a trusted adviser to both listed corporates and investment banks. David has a wealth of experience on flotations and secondary offerings, both issuer and bank-side.

David has spent time on secondments in Paris and with the RBS Hoare Govett M&A/Equity Originations teams.

  • Private equity and venture capital
  • Public and private M&A
  • Equity capital markets
  • Corporate

Advised AIMCo on its £300 million joint venture acquisition and development financing for the BBC Television White City site with Mitsui Fudosan and Stanhope.

Advised Ontex International on its £1 billion acquisition by TPG and Goldman Sachs.

Advised AMP Capital on its successful £200 million consortium bid with JV partner 3i Infrastructure for Danish emergency and rescue services provider Esvagt.

More: Private equity and venture capital

Advised J.P. Morgan Cazenove as lead financial adviser and sole sponsor on Micro Focus International plc's $8.8 billion merger with the software business segment of Hewlett Packard Enterprises.

Acted for Vectura Group (bidder) on its recommended merger with peer company Skyepharma plc, valuing Skyepharma at £440 million.

Advised Xchanging on takeover offers for it by Capita, Ebix and its eventual £480 million takeover by Computer Sciences Corporation.

Advised Xchanging on its £64.1 million acquisition of the European operations of US-headquartered insurance software company Agencyport Software.

Advised Ontex International on its £1 billion acquisition by TPG and Goldman Sachs.

Advised Babcock International Group on its £350 million acquisition of Devonport Management from Kellogg Brown & Root Holdings, Balfour Beatty and The Weir Group.

Acted for Lloyds Banking Group on the sale to Goldman Sachs of a portfolio of finance assets and equity interests (book value of £1.2 billion).

More: Public and private M&A

Acted for life and pensions consolidator Chesnara plc on its £70 million placing and open offer in connection with its €160 million acquisition of L&G Nederland.

Advised Jefferies International as sponsor and joint bookrunner on Oxford Biomedica's £10 million firm placing, placing and open offer.

Advised selling shareholder Elliott Advisers in connection with GAME Digital's £110 million main market IPO and subsequent block trades.

Advised issuer Cambian Healthcare on its £190 million main market IPO.

Advised J.P. Morgan Cazenove, financial adviser to Invensys plc on its £625 million return of cash following the £1.7 billion disposal of its Rail Division to Siemens.

Advised issuer Bayfield Energy Holdings on its £55 million raise and listing on AIM.

Advised Central Asia Metal's £40 million raise and listing on AIM.

More: Equity capital markets

Acted for Vectura Group on its recommended merger with peer company Skyepharma plc, valuing Skyepharma at £440 million.

Acted for life and pensions consolidator Chesnara plc on its £70 million placing and open offer in connection with its €160 million acquisition of L&G Nederland.

Advised Xchanging on takeover offers for it by Capita, Ebix and its eventual £480 million takeover by Computer Sciences Corporation.

Issuer's counsel to Cambian Healthcare on its £190 million main market IPO.

More: Corporate

  • TMT
  • Mining and minerals
  • Oil and gas
  • Energy and natural resources
  • Healthcare

Advised business processing, procurement and technology services provider Xchanging on its £64.1 million acquisition of Agencyport Software.

Advised Xchanging on its £13 million acquisition of spend analytics company Spikes Cavell.

Counsel to Credit Suisse Securities (Europe), J.P. Morgan Securities and Jefferies International as joint bookrunners on Intel's £51.25 million block trade placing of shares in FTSE 250 Imagination Technologies Group.

Advised selling shareholder Elliott Advisers in connection with GAME Digital's £110 million main market IPO.

More: TMT

Advised AIM-listed Central Asia Metals on its acquisition of the remaining 40 per cent interest in its Kounrad copper project in Kazakhstan.

Acted for Ferrexpo in its acquisition of a further equity stake in Ferrous Resources.

Issuer's counsel on Central Asia Metal's £40 million AIM listing.

More: Mining and minerals

Advised issuer Bayfield Energy Holdings on its £55 million raise and listing on AIM.

Acted for Macquarie Capital (Nomad) on AIM-listed San Leon Energy plc's £60 million undocumented placing.

Advised Canaccord Genuity as broker to Pitkin Petroleum on its US$20 million private placement.

More: Oil and gas

Advised Infinis Energy as purchaser of 18.5 Mega-Watt consented "Maidens Hall/Steadsburn" onshore wind farm project from Peel Group.

Advised AMP Capital on its successful £200 million consortium bid with JV partner 3i Infrastructure for Danish emergency and rescue services provider Esvagt.

Acted for Ferrexpo in its acquisition of a further equity stake in Ferrous Resources.

More: Energy and natural resources

Acted for Vectura Group on its recommended merger with peer company Skyepharma plc, valuing Skyepharma at £440 million.

Acted for Jefferies International as sponsor and joint bookrunner on Oxford Biomedica's £10 million firm placing and placing and open offer.

Advised Cambian Healthcare on its £190 million raising and main market IPO.

More: Healthcare

print-footer
logo
© Stephenson Harwood LLP 2016. Any reference to Stephenson Harwood in this document means Stephenson Harwood LLP and/or its affiliated undertakings. Any reference to a partner is used to refer to a member of Stephenson Harwood LLP.